Stephen A. Krahling and Joan A. Wlochowski, former Merck virologists blew the whistle by filing a qui tam action lawsuit — U.S. v Merck & Co. — in August 2010. The scientists allege that the efficacy tests for the measles, mumps, rubella . . . Continue reading →
Bernice Eddy, PhD (1903–1989) a virologist and epidemiologist at NIH, identified SV40, a cancer-causing monkey virus that millions of children were exposed to from contaminated polio vaccines. In 1954, while the NIH was testing the first commercial polio vaccines, Eddy’s job was . . . Continue reading →
David Graham, MD, FDA’s Associate Director of Science and Medicine who, throughout his career, has been a thorn for FDA managers by identifying hazardous drug effects. In 1999, his data helped identify the risk of liver damage from Pfizer’s diabetes drug Rezulin . . . Continue reading →
Professor and chair of the department of Family and Geriatric Medicine at the University of Louisville. From 2009 to 2013 she was a professor at the University of Missouri Kansas City’s department of Biomedical and Health Informatics. From 1996 to 2009 she . . . Continue reading →
“No name in contemporary English medicine is greeted with such polarized reactions as that of Dr. Andrew Wakefield” *read: L’affaire Wakefield: Shades of Dreyfus & BMJ’s Descent into Tabloid Science Andrew Wakefield, MD, an academic gastroenterologist, trained at St. Mary’s Hospital Medical School, . . . Continue reading →
Anthrax Vaccine: Its checkered history, excessive stockpile and the human and financial costs By Meryl Nass, MD* The current vaccine (Biothrax, manufactured by Emergent Biosolutions or EBS) has never been proved effective in humans. One human trial took place in the 1950s . . . Continue reading →
“Unfortunately, the entire evidence base has been perverted,” said Joseph Ross, a professor at Yale Medical School who has studied the issue. Continue reading →
Update: America’s Healthcare Crisis–7 Scientists Quit Cancer Prevention Research Institute of Texas Continue reading →
Part III. The Untouchable Third Rail in Healthcare—The Vaccine Controversy: Core Issues Continue reading →
The decision to suspend the trial is viewed as highly questionable, raising disturbing questions about the role that marketing played–especially in light of the fact that Zytiga’s patent is due to expire in 2017.
A strong case for the anthrax vaccine trial would be made “if the community that’s most supportive of moving this forward would volunteer their own children for the study.”Amy Gutmann,Chair, Presidential Commission for the Study of Bioethical Issues.
100 Amgen scientists were astonished to find that they were able to replicate the results of only 6 of 53 widely cited landmark cancer research papers.
Continue reading →